US › Healthcare

Protalix Biotherapeutics Inc (PLX)

US · Healthcare · Biotechnology

$2.54+1.20%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$19.9M

Revenue YoY

+27.1%

Net profit

$3.8M

Profit YoY

+2203.0%

EPS

$0.05

EPS estimate

$-0.01

Net margin

19.0%

EPS came in at 0.05 against a street estimate of -0.01 — a beat of 600.0%.

Key statistics

Market cap

$202.2M

P/E

10.9

Forward P/E

53.8

P/B

3.04

Book value

$0.89

EPS (TTM)

$0.23

52-week high

$3.19

52-week low

$1.65

50-day MA

$2.66

200-day MA

$2.42

Beta

-0.02

Analyst view

Analysts rate Protalix Biotherapeutics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $11.00.

Shareholding

Insiders

3.88%

Institutions

24.22%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Protalix Biotherapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.